Clinical trials: Advanced Solid Malignancy
Advanced Solid Tumor, Lung Squamous Cell Carcinoma
JMT106 Injection in the Treatment of Advanced Solid Tumors
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Lung Squamous Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT07275073
- Testing
- JMT106 Injection
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai JMT-Bio Inc.
Gastric Cancer, Renal Cell Carcinoma
A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors
The purpose of this study is to test the safety and tolerability of HFB200301 as a single agent and in combination with tislelizumab in patients with advanced cancers. There are two parts in this study.
- Conditions
- Gastric Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma
- Trial name
- NCT05238883
- Testing
- HFB200301, Tislelizumab
- Where
- 10 sites in United States, Spain
- Volunteers
- 72 people
- Sponsor
- HiFiBiO Therapeutics
Solid Tumor
Safety Study of PLX108-01 in Patients With Solid Tumors
PLX3397 is a selective inhibitor of Fms, Kit, and oncogenic Flt3 activity. The primary objective of this study is to evaluate the safety and pharmacokinetics of orally administered PLX3397 in patients with advanced, incurable…
- Trial name
- NCT01004861
- Testing
- PLX3397
- Where
- 13 sites in United States
- Volunteers
- 132 people
- Sponsor
- Daiichi Sankyo
Advanced Solid Tumor
Effect of Rifampicin on the Pharmacokinetics of HRS-1167 in Healthy Subjects
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy adult subjects after oral administration of HRS-1167 tablets.
- Trial name
- NCT06198556
- Testing
- HRS-1167 tablets; rifampicin
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Advanced Malignant Solid Tumours
A Study of RT023 in Patients With Advanced Solid Tumors
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of RT023 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT07797426
- Testing
- RT023
- Volunteers
- 318 people
- Sponsor
- Shanghai Ruotuo Biosciences Co., Ltd.
Solid Tumor
A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of EU103 in Advanced or Metastatic Solid Tumors That Have Failed Standard Therapy
Phase 1 (dose escalation) of this study will evaluate: The safety and tolerability of EU103 treatment are evaluated for patients with advanced or metastatic solid tumors who have failed standard therapy to determine the maximum…
- Trial name
- NCT05798026
- Testing
- EU103
- Where
- 3 sites in South Korea
- Volunteers
- 15 people
- Sponsor
- Eutilex
Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment
A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)
The purpose of this study is to investigate the PK and safety of NKTR-102 in patients with mild, moderate, or severe hepatic impairment.
- Trial name
- NCT01991678
- Testing
- 145 mg/m2 NKTR 102, 120 mg/m2 NKTR 102, 50 mg/m2 NKTR 102
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Nektar Therapeutics
Advanced Solid Tumors
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors.
- Trial name
- NCT05905614
- Testing
- SPH4336 Tablets
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Solid Tumor
A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors
This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors.
- Trial name
- NCT06993116
- Testing
- SHR-4712 Injection
- Where
- 2 sites in China
- Volunteers
- 15 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Solid Tumor
A Study of IBI3004 in Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
This is an open-label, multicenter, dose escalation and expansion phase I /II study of IBI3004 in subjects with unresectable, locally advanced or metastatic solid tumors.
- Trial name
- NCT06198426
- Testing
- IBI3004
- Where
- 5 sites in Australia, China
- Volunteers
- 5 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Non-small Cell Lung Cancer, Colorectal Carcinoma
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.
- Conditions
- Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
- Trial name
- NCT06218914
- Testing
- NT-112: Autologous, engineered T Cells targeting KRAS G12D, AZD0240: Autologous, engineered T Cells targeting KRAS G12D
- Where
- 18 sites in United States
- Volunteers
- 108 people
- Sponsor
- AstraZeneca
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Solid Neoplasms
Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
The purposes of this study are to determine the safety and tolerability of MK-7162 when administered in combination with pembrolizumab (MK-3475) and to establish a preliminary recommended Phase 2 dose (RP2D) of MK-7162 when…
- Trial name
- NCT03364049
- Testing
- MK-7162, Pembrolizumab
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Solid Malignancies
Modular Study to Evaluate CT7001 Alone in Cancer Patients With Advanced Malignancies
This is a modular, Phase I/II, multicentre study to investigate CT7001 monotherapy in advanced solid malignancies and to further investigate CT7001 as monotherapy or in combination with standard therapy in specific participant…
- Trial name
- NCT03363893
- Testing
- CT7001, Fulvestrant
- Where
- 23 sites in United States, United Kingdom
- Volunteers
- 124 people
- Sponsor
- Carrick Therapeutics Limited
Advanced Solid Tumor
A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetics and treatment effect of CS1001 in combination with Donafenib in patients with advanced solid tumors.
- Trial name
- NCT04472858
- Testing
- Donafenib, CS1001
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Advanced Solid Tumor
Study of APR-1051 in Patients With Advanced Solid Tumors
The purpose of this study is to assess the safety and effectiveness of APR-1051 through the performance of a Phase 1, open-label, safety, PK, and preliminary efficacy study of oral APR-1051 in patients with advanced solid tumors.
- Trial name
- ACESOT-1051 (NCT06260514)
- Testing
- APR-1051
- Where
- 7 sites in United States
- Volunteers
- 90 people
- Sponsor
- Aprea Therapeutics
Advanced Solid Tumors
A Study of KC1036 in Patients with Advanced Solid Tumors
The purpose of this study is to evaluate the safety，tolerability, pharmacokinetics, and preliminary efficacy of KC1036 in participants with advanced recurrent or metastatic solid tumors.
- Trial name
- NCT04387916
- Testing
- KC1036
- Where
- 3 sites in China
- Volunteers
- 207 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Advanced Malignant Solid Tumors
Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors
This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors
- Trial name
- NCT03792958
- Testing
- CM082
- Where
- China
- Volunteers
- 19 people
- Sponsor
- AnewPharma
Solid Tumor, Adult
Study of FCN-437c in Patients With Advanced Solid Tumors
This research study is studying a drug called FCN-437c as a possible treatment for patients with advanced unresectable/metastatic solid tumors.
- Trial name
- FCN-437c (NCT03951116)
- Testing
- FCN-437
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Fochon Pharmaceuticals, Ltd.
Solid Tumors
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or…
- Trial name
- NCT03539484
- Testing
- RO7172508, Obinutuzumab, Tocilizumab
- Where
- 6 sites in Belgium, Canada and 2 more
- Volunteers
- 26 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.